The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $6.88 in the last session, up 5.36% from day before closing price of $6.53. In other words, the price has increased by $5.36 from its previous closing price. On the day, 12.75 million shares were traded. RXRX stock price reached its highest trading level at $7.17 during the session, while it also had its lowest trading level at $6.6641.
Ratios:
We take a closer look at RXRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.35 and its Current Ratio is at 4.35. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 17 ’25 when Secora Michael bought 5,000 shares for $6.51 per share.
Secora Michael bought 15,000 shares of RXRX for $98,519 on Jan 15 ’25. On Jan 14 ’25, another insider, Secora Michael, who serves as the Former Officer of the company, bought 15,000 shares for $6.48 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2688167168 and an Enterprise Value of 1636425088. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.25 while its Price-to-Book (P/B) ratio in mrq is 3.75. Its current Enterprise Value per Revenue stands at 25.105 whereas that against EBITDA is -4.494.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.84, which has changed by -0.36969113 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $15.74, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is -0.36%, while the 200-Day Moving Average is calculated to be -7.98%.
Shares Statistics:
According to the various share statistics, RXRX traded on average about 12.10M shares per day over the past 3-months and 14865350 shares per day over the past 10 days. A total of 390.76M shares are outstanding, with a floating share count of 323.81M. Insiders hold about 17.13% of the company’s shares, while institutions hold 57.90% stake in the company. Shares short for RXRX as of 1735603200 were 73735739 with a Short Ratio of 6.10, compared to 1732838400 on 67845763. Therefore, it implies a Short% of Shares Outstanding of 73735739 and a Short% of Float of 20.580000000000002.
Earnings Estimates
The market rating of Recursion Pharmaceuticals Inc (RXRX) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.34 and low estimates of -$0.8.
Analysts are recommending an EPS of between -$1.22 and -$1.9 for the fiscal current year, implying an average EPS of -$1.54. EPS for the following year is -$1.64, with 9.0 analysts recommending between -$1.28 and -$2.9.
Revenue Estimates
According to 7 analysts, the current quarter’s revenue is expected to be $18.17M. It ranges from a high estimate of $34M to a low estimate of $8M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $10.89MFor the next quarter, 7 analysts are estimating revenue of $12M. There is a high estimate of $15M for the next quarter, whereas the lowest estimate is $6M.
A total of 9 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $88.3M, while the lowest revenue estimate was $44.61M, resulting in an average revenue estimate of $67.14M. In the same quarter a year ago, actual revenue was $44.58MBased on 9 analysts’ estimates, the company’s revenue will be $76.34M in the next fiscal year. The high estimate is $175M and the low estimate is $12.77M.
